Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature

Gaetano Zaccara1, Luigi M Specchio21Unit of Neurology, Palagi Hospital, Firenze, Italy; 2University of Foggia, Ospedali Riuniti, Foggia, ItalyAbstract: Zonisamide (ZNS) efficacy and safety in epilepsy have been demonstrated in four double-blind, placebo-controlled studies. In the present article, we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gaetano Zaccara, Luigi M Specchio
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/6c86e20f645742899a1fa4950ebb98cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c86e20f645742899a1fa4950ebb98cb
record_format	dspace
spelling	oai:doaj.org-article:6c86e20f645742899a1fa4950ebb98cb2021-12-02T03:13:28ZLong-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature1176-63281178-2021https://doaj.org/article/6c86e20f645742899a1fa4950ebb98cb2009-04-01T00:00:00Zhttp://www.dovepress.com/long-term-safety-and-effectiveness-of-zonisamide-in-the-treatment-of-e-a3078https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Gaetano Zaccara1, Luigi M Specchio21Unit of Neurology, Palagi Hospital, Firenze, Italy; 2University of Foggia, Ospedali Riuniti, Foggia, ItalyAbstract: Zonisamide (ZNS) efficacy and safety in epilepsy have been demonstrated in four double-blind, placebo-controlled studies. In the present article, we examined all long-term studies performed with this drug. Nine open-label studies, in which ZNS had been administered as an add-on or as monotherapy to epileptic patients for at least 6 months, were selected for our analysis. Four outcome measures were searched. Retention of this drug after 1 year varied between 45% and 65%. The percentages of patients achieving a 50% seizure reduction, with respect to baseline, ranged between 37% and 65%. In patients with drug-resistant forms of epilepsy, the percentage of patients reaching a 6-month seizure freedom period was 9%. The percentages of patients who discontinued the experimental drug due to adverse effects ranged between 4% and 24%. Somnolence and dizziness were the most frequently reported adverse effects. Long-term studies demonstrate that ZNS has a good efficacy and tolerability profile, and support its use as adjunctive therapy for epileptic patients.Keywords: antiepileptic drugs, zonisamide, long-term treatment, review, epilepsy Gaetano ZaccaraLuigi M SpecchioDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 249-259 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Gaetano Zaccara Luigi M Specchio Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
description	Gaetano Zaccara1, Luigi M Specchio21Unit of Neurology, Palagi Hospital, Firenze, Italy; 2University of Foggia, Ospedali Riuniti, Foggia, ItalyAbstract: Zonisamide (ZNS) efficacy and safety in epilepsy have been demonstrated in four double-blind, placebo-controlled studies. In the present article, we examined all long-term studies performed with this drug. Nine open-label studies, in which ZNS had been administered as an add-on or as monotherapy to epileptic patients for at least 6 months, were selected for our analysis. Four outcome measures were searched. Retention of this drug after 1 year varied between 45% and 65%. The percentages of patients achieving a 50% seizure reduction, with respect to baseline, ranged between 37% and 65%. In patients with drug-resistant forms of epilepsy, the percentage of patients reaching a 6-month seizure freedom period was 9%. The percentages of patients who discontinued the experimental drug due to adverse effects ranged between 4% and 24%. Somnolence and dizziness were the most frequently reported adverse effects. Long-term studies demonstrate that ZNS has a good efficacy and tolerability profile, and support its use as adjunctive therapy for epileptic patients.Keywords: antiepileptic drugs, zonisamide, long-term treatment, review, epilepsy
format	article
author	Gaetano Zaccara Luigi M Specchio
author_facet	Gaetano Zaccara Luigi M Specchio
author_sort	Gaetano Zaccara
title	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
title_short	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
title_full	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
title_fullStr	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
title_full_unstemmed	Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
title_sort	long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/6c86e20f645742899a1fa4950ebb98cb
work_keys_str_mv	AT gaetanozaccara longtermsafetyandeffectivenessofzonisamideinthetreatmentofepilepsyareviewoftheliterature AT luigimspecchio longtermsafetyandeffectivenessofzonisamideinthetreatmentofepilepsyareviewoftheliterature
_version_	1718401859382673408

Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature

Ejemplares similares